SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
XCUR
--
0.00%
--
Checkmate Pharmaceuticals Begins IPO Process
Seeking Alpha · 2d ago
Exicure, Inc. (XCUR): Hedge Funds Sticking Around
Insider Monkey · 07/05 20:30
Exicure, Inc. Added to Russell 2000® Index
Business Wire · 06/29 12:00
Exicure Presents Cavrotolimod (AST-008) Clinical Data at AACR 2020 Virtual Meeting
Exicure is presenting updated pharmacodynamic and safety data at the American Association of Cancer Research (AACR) Virtual Annual Meeting II.
Business Wire · 06/22 11:00
Exicure, Inc. to Present at the 2020 BMO Prescription for Success Healthcare Conference
Business Wire · 06/18 12:00
Dosing underway in Exicure's mid-stage merkel cell carcinoma trial of AST-008
Seeking Alpha - Article · 06/16 12:24
Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)
Business Wire · 06/16 12:00
Exicure Announces First Patient Dosed In Phase 2 Merkel Cell Carcinoma Trial Of Cavrotolimod (AST-008)
Benzinga · 06/16 11:05
Week 25 MDA Breakout Forecast: Short-Term Stocks To Give You An Edge
Seeking Alpha - Article · 06/14 06:23
3 Strong Buy Penny Stocks That Could See Outsized Returns
TipRanks · 06/04 14:46
Exicure, Inc. to Present at Jefferies 2020 Healthcare Conference
Business Wire · 05/20 12:00
Exicure Announces Appointment of Dr. Douglas E. Feltner as Chief Medical Officer
Business Wire · 05/19 12:00
Despite Lacking Profits Exicure (NASDAQ:XCUR) Seems To Be On Top Of Its Debt
Simply Wall St. · 05/15 16:50
Exicure to Present Clinical Data at AACR 2020 Virtual Meeting
Business Wire · 05/15 12:00
Exicure Highlights Presentation Of Clinical Data At AACR Meeting Jun. 22-24
Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, will present at the American Association of Cancer Research (AACR) Virtual
Benzinga · 05/15 11:01
Exicure to Present at the American Society of Clinical Oncology 2020
Business Wire · 05/14 12:00
Exicure Q1 EPS $0.010 Up From $(0.120) YoY, Sales $9.183M Up From $25.000K YoY
Exicure (NASDAQ:XCUR) reported quarterly earnings of $0.010 per share. This is a 108.33 percent increase over losses of $(0.120) per share from the same period last year. The company reported $9.183 million in sales
Benzinga · 05/14 10:04
Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting
Business Wire · 05/05 12:00
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board
Business Wire · 04/07 12:00
Such Is Life: How Exicure (NASDAQ:XCUR) Shareholders Saw Their Shares Drop 56%
Simply Wall St. · 03/19 15:39